Skip to content

Transurethral Selective Green Laser Vaporization for Refractory Overactive Bladder in Women: Mechanisms and Clinical Efficacy from a Retrospective Study

Retrospective Study on the Mechanism and Clinical Efficacy of transurethral GreenLight laser-selective vaporization for refractory overactive bladder in women

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600125692
Enrollment
Unknown
Registered
2026-05-29
Start date
2026-06-30
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory Overactive Bladder (OAB)

Interventions

Refractory OAB transurethral selective green laser vaporization Pre-post Intervention Study:None

Sponsors

Shandong Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1.Unable to tolerate more than one anticholinergic drug, or ineffective after 3 months of anticholinergic drug treatment; 2.Adult female patients with overactive bladder who did not achieve the expected therapeutic effect after sacral nerve regulation, percutaneous tibial nerve stimulation or intramural botulinum toxin type A injection.

Exclusion criteria

Exclusion criteria: 1. Combined with mental illness or severe physical illness; 2. Combined with bladder outlet obstruction; 3. Concurrent urinary tract infections, calculi and other urological diseases; 4. Have undergone urogenital system surgery within the past three months; 5. Pregnancy or pregnancy plans during the study period; 6. Ultrasound examination indicates residual urine volume > 100mL or concurrent pulmonary disease; 7. Have a history of brain tumor surgery, spinal cord injury, or have been diagnosed with multiple sclerosis, Alzheimer's disease, stroke, Parkinson's disease and other neurological diseases; 8. Patients who could not tolerate the relevant treatment procedures in this study.

Design outcomes

Primary

MeasureTime frame
quantitative alterations of key molecular proteins (ZO-1, E-cadherin,p-p65, TRPA1/NLRP3);

Secondary

MeasureTime frame
Changes in clinical symptoms (e.g., ?OABSS);

Countries

China

Contacts

Public ContactZhao Yong

Shandong Provincial Hospital (Shandong Children's Hospital)

zhaoyong6807@163.com+86 531 68773153

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026